Trial closed early
ROCHESTER
, MN - The Mayo Clinic Cancer Center announced that a multiple myeloma clinical trial has shown a significant survival improvement with lenalidomide plus low-dose dexamethasone therapy versus lenalidomide plus high-dose dexamethasone. The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute studied combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had a one-year survival rate of 86%. The therapy using low-dose dexamethasone showed a 96.5% overall survival rate at one year, with much less toxicity. “This is the best one-year survival data I’ve seen in a large Phase
III
study in myeloma,” said Dr. Vincent Rajkumar, Mayo Clinic hematologist and ECOG study primary investigator. “This is a major advance in the treatment of this cancer.” All patients on the high-dose dexamethasone arm of the clinical trial will be moved to the low-dose arm. A successor study using lenalidomide plus high-dose dexamethasone was closed early as a result of these findings.
----------------------
NEW
YORK
- HealthDay News noted some clinical trials from Thomson Center Watch: Pregnancy complications - Females with pre-eclampsia may be eligible to participate if at least 16 years old and the fetus is gestational 10 to 16 weeks. Candidates may not participate if they’ve had organ transplant, pre-existing proteinuria, use of anti-retroviral medication, a history of illicit drug abuse, or participation in another research study within the prior 30 days. The research is in
New York City
. Visit www.centerwatch.com/patient/studies/cat650.html. High Blood Pressure - This study will compare reduction in systolic blood pressure using a valsartan/hydrochlorothiazide regimen versus an amlodipine/hydrochlorothiazide regimen in people with stage 2 hypertension. Participants must be 18 or older, diagnosed with hypertension, and capable of providing written informed consent to participate. Females must be either post-menopausal for one year, surgically sterile, or use effective contraceptive methods. Other criteria apply. The research site is in
Lexington
,
KY.
Visit www.centerwatch.com/patient/studies/cat85.html. Migraine and cluster headaches - This study will evaluate a one-dose investigational medication to treat migraine headaches. Participants must be 18 or older and have had at least one migraine per month in the last two months. They will receive, at no cost, study-related physical exams, lab tests, and ECG. The research site is in
Lake Jackson
,
TX
. Visit www.centerwatch.com/patient/studies/cat100.html.
